• Researchers Tapping the Genome to Extend Life and Reverse Disease

    Nov 19 | Bio-IT World | As has been extensively demonstrated in mice, it is entirely possible to slow or reverse biological aging. Work currently underway in George Church’s lab at Harvard University’s Wyss Institute for Biologically Inspired Engineering aims to take interventions that makes aged cells and tissues “function younger” into treatments for humans plagued by an assortment of age-related diseases. More
  • Breast Cancer Prevention Strategy to be Tested in Young Women

    Nov 17 | Bio-IT World | Researchers are leveraging involution, the natural biological clean-up and remodeling process that happens after a woman stops breastfeeding, in a quest to prevent breast cancer in young, high-risk women. The immediate postpartum period introduces a temporary, sharp increase in cancer risk—most notably, for women who have BRCA1 genetic mutations. More
  • UCB Taps Cradle for AI Antibody Design, Insilico Medicine Releases Open Source Longevity AI System

    Nov 14 | Bio-IT World | Boston Children's Hospital and the University of Oxford to lead a $46M Genetic Medicines Hub within the ARIA autism research ecosystem; MD Anderson partners with P-Cure on compact proton and helium ion therapy; Takeda joins ISSCR consortium on stem cell-based models for drug discovery; Harvard Medical School team builds AI co-scientists for cancer research; Ascidian taps Exegenesis Bio for AAV capsids; new products from IDT, Aldevron, Lab Thread, and Licklider; and more. More
  • A LEGO-style approach to building virus-like particles in insect cells

    Nov 13 | Bio-IT World | Maren Schubert’s lab at the Helmholtz Center for Infection Research has spent a decade refining an alternative to the field’s default route for making virus-like particles (VLPs) in insect cells. Her solution: skip the virus. More
  • Biosecurity Is Too Important to Be Left Unregulated

    Nov 11 | Bio-IT World | Recently, California became the first state to enact a law requiring nucleic acid synthesis companies to screen sequences and vet customers before delivering their products. California is a pioneer in creating enforceable regulations of nucleic acid synthesis screening. Unfortunately, it’s not enough. More
  • NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation

    Nov 10 | Bio-IT World | A Pitt cardiologist’s startup, Amlysion Therapeutics, plans to develop NCOA7-activating drugs after new research traces cognitive decline in pulmonary hypertension to the same inflammatory pathway that drives the disease in the heart and lungs. More
  • Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award

    Nov 07 | Bio-IT World | HuBMAP data portal opens 9,000 healthy-tissue datasets to researchers; NCI awards Montefiore Einstein $10 million to study breast cancer dormancy; UCB adds Cradle's protein design platform across its antibody discovery pipeline; NIH funds a $16.4 million hepatitis C vaccine center at Scripps Research; Transpharmation acquires organoid developer OrganoTherapeutics; new gene editing products from Integrated DNA Technologies and Aldevron; and more. More
  • Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences

    Nov 05 | Bio-IT World | Emerging public-cloud ERP-based GxP compliance solutions will be good for life sciences businesses beyond just sharply reducing compliance overhead. Public-cloud ERP GxP will ensure product quality and patient safety, speed up innovation, stoke growth, appeal to investors, improve responsiveness to market moves, smooth M&A efforts, and enable AI-driven efficiencies. More
  • Quantifying the Average Human Genome

    Nov 03 | Bio-IT World | Mining two mega-datasets totaling over 900,000 sequenced genomes, researchers in the UK produced the broadest look yet at what a typical human genome contains and found that “normal” can look alarming on paper. “Variation is the norm,” they found. The work was published October in Genome Medicine. More
  • Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing

    Oct 29 | Bio-IT World | Every major pharma organization I’ve come across in recent years has its own version of the same AI-based ambition. It is looking to use the technology to compress the R&D timeline, reduce late-stage attrition, and make regulatory submissions faster and inspections less tense. And yet, almost without exception, progress will stall because the product data foundations are flawed. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Corning® MSCulture Max™ Media

Corning’s MSCulture Max media increases final hMSC yields, streamlines culture, reduces in-process risk, and eliminates media exchanges, enabling higher cell expansion with less media and fewer media changes. The MSCulture Max media consists of a basal medium and supplement with 3 versions available:

  • Standard research-grade medium for MSC expansion
  • Xeno-free medium optimized for rapid MSC expansion
  • Xeno-free GMP-grade medium for bioproduction
Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!